Source

Janssen Infectious Diseases BVBA, Beerse, Belgium. rvheesw1@its.jnj.com.

Abstract

Hepatitis C Virus (HCV) infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV co-infected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype 1 mono-infected patients, and studies in HCV/HIV co-infected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarises the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate, and raltegravir.